TABLE 6.

Results obtained in reversion study^a

Group	Dose (no. of CFU/mouse)	Study day	Wt gain (g)b	Stomach wt (g)d	No. of animals with increase in following characteristic/total no. animals per group:			No. of DNA copies of H. pylori/stomachd	Total no. of ulcers/stomach	H. pylori pathogenicity ratioc,d
					Peyer's patches	Spleen wt	Mesenteric ganglion wt
A	Placebo	14	−0.90 ± 0.60	0.174 ± 0.035 D	4/5	1/5	1/5	2.1 × 106 ± 1.9 × 106 F	1.00 ± 0.71	0.85 ± 0.90 H
		21	0.06 ± 0.45	0.132 ± 0.032 D	5/5	0/5	1/5	3.6 × 107 ± 6.0 × 107 F	0.60 ± 0.89	0.02 ± 0.03 H
B	1 × 109	14	−0.36 ± 0.76	0.166 ± 0.038 E	2/5	0/5	0/5	4.4 × 106 ± 3.5 × 106 G	0.60 ± 0.55	0.13 ± 0.14 I
		21	−0.20 ± 0.37	0.132 ± 0.013 E	2/5	0/5	0/5	4.9 × 107 ± 3.0 × 107 G	0.00 ± 0.00	0.00 ± 0.00 I

^aData are the means ± standard deviations of the means (n = 5).

^bBody weight gain is expressed as final weight minus initial weight.

^cH. pylori pathogenicity ratio is expressed as total number of ulcers per million copies of H. pylori DNA in the stomach.

^dPairs of values sharing the same capital letter are significantly different (P < 0.05).